The global Pain Patch Market Growth Accelerated by Rise in Chronic Pain Cases
Pain patches are topical patches that provide pain relief by delivering medication such as lidocaine, diclofenac, and ibuprofen through the skin. They are easy to apply, cost-effective, and provide long-lasting relief. These properties make them suitable for pain management associated with migraines, backaches, joint pains, and arthritis.
The global Pain Patch Market is estimated to be valued at
US$ 5.29 Bn in 2023 and is expected to exhibit a CAGR of 5% over the forecast
period 2023-2030, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
The increasing incidences of chronic pain worldwide is one of the key factors
driving the growth of the pain patch market. Chronic pain affects millions of
people globally and leads to diminished quality of life if not treated
appropriately. Pain patches provide long-lasting relief from chronic pain and
are easier to use compared to oral drugs. Their ease of use and ability to
deliver drugs locally makes them an attractive treatment option for chronic
pain sufferers. As chronic conditions like arthritis and back pain continue to rise,
demand for new pain relief options like pain patches is expected to grow
significantly over the forecast period.
Segment
Analysis
The global pain patch market is dominated by the back pain sub-segment owing to
rising incidence of lower back pain primarily caused by obesity and increasing
geriatric population. Back pain contributes to over 20% of the total pain patch
market share globally as lower back pain is a common diagnosis across
countries.
Key Takeaways
The global pain
patch market is expected to witness high growth over the forecast period
2023-2030. The global Pain Patch Market is estimated to be valued at US$ 5.29
Bn in 2023 and is expected to exhibit a CAGR of 5% over the forecast period
2023-2030.
Key players: Key players operating in the pain patch market are Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Pfizer Inc., Novartis AG, Mylan N.V., Endo Pharmaceuticals, Teikoku Pharma USA, Inc., Acorda Therapeutics, Ibsa Institut Biochimique SA, Alembic Pharmaceuticals, Noven Pharmaceuticals, Inc., Teva Pharmaceuticals, Strativa Pharmaceuticals, Galen Limited, and Napp Pharmaceuticals. Hisamitsu Pharmaceutical Co. leads the market and enjoys the dominant market share in the global pain patch space due to its robust distribution channels and diverse pain patch product portfolio catering to varied pain indications.
Comments
Post a Comment